Hypoxic radiosensitizers/Sanazole/Nimorazole/KU-2285.
INTRODUCTION
Hypoxic cells or hypoxic cell foci exist in various experimental and human tumors, [1] [2] [3] and tumor hypoxia is now known as an important factor that negatively influences prognosis of cancer patients. 4) Hypoxic tumor cells are not only resistant to ionizing radiation and many chemotherapeutic agents, but are also ready to metastasize to distant organs. 5, 6) To overcome the problem of tumor hypoxia, various strategies have been attempted; one of classical approaches is the use of hypoxic cell radiosensitizers. Numerous new compounds of this class have been developed and tested in the clinic, but clinical usefulness of these compounds remains uncertain. [7] [8] [9] [10] [11] [12] [13] Since it seems difficult to develop new hypoxic cell sensitizers that are more efficient than currently available ones, appropriate clinical trials with the existing compounds should be planned to conclude the clinical usefulness of hypoxic cell sensitizers. These agents are expected to be more effective when combined with large single doses of radiation than with conventional radiotherapy, mainly because reoxygenation takes place in the latter. 14) With the development of stereotactic radiosurgery, larger radiation doses per fraction are more frequently used than ever before. Therefore, clinical trials on the combination of hypoxic cell sensitizers and radiosurgery appear to be worthwhile. 15) Among currently-available hypoxic cell sensitizers, newly-developed sanazole (AK-2123, 3-nitrotriazole derivative, N 1-(3-methoxypropyl)-2-(3-nitro-1 H -1,2,4-triazol-1-yl)acetamide) and nimorazole (5-nitroimidazole derivative, 4-(2-(5-nitro-1 H -1-imidazolyl)ethyl)morpholine) which has been used as an anti-trichomonal agent have been tested clinically mainly outside Japan. A fluorinated 2-nitroimidazole derivative KU-2285 ( N 1-(2-hydroxyethyl)-1,2-difluoro-3-(2-nitro -1 H -1-midazolyl)propanamide) has been tested in combination with conventional radiotherapy and intraoperative radiation at Kyoto University. 12, 13) This compound may be one of the best compounds in terms of high efficacy and low toxicity. [16] [17] [18] [19] [20] A 2-nitroimidazole nucleoside analogue doranidazole (PR-350) has undergone phase II/III clinical studies in combination with conventional radiotherapy for locallyadvanced lung cancer and in combination with intraoperative radiotherapy for unresectable pancreatic cancer, but future prospects of clinical trials with this compound are unclear. 21, 22) All of these compounds are believed to show radiosensitizing effects by fixing radiation-induced damage under hypoxic conditions as a substitute of oxygen. 23) Since the terms of patent license for newly-developed sanazole and KU-2285 will expire soon, pharmaceutical companies are not willing to conduct clinical trials, which usually take several years, with these compounds. Therefore, clinical studies of hypoxic cell sensitizers may better be carried out with readily and cheaply obtainable compounds. Since KU-2285 is not readily obtained for clinical use because of relatively difficult synthesizing process and high cost for synthesis, we paid attention to sanazole and nimorazole. Sanazole has been distributed worldwide through the International Atomic Energy Association and nimorazole is commercially available. Raw materials for synthesis of these two compounds are cheap.
There have been several basic investigations evaluating the efficacy of the two radiosensitizers, [24] [25] [26] [27] [28] [29] and clinical trials on these two compounds have been carried out in several countries other than Japan based on the preclinical studies. 11, 30, 31) However, we felt further preclinical studies are needed on these compounds to decide to conduct clinical studies. In this study, therefore, we investigated radiosensitizing effects of sanazole and nimorazole in vitro and in vivo , in comparison with the effect of KU-2285 which has been more extensively evaluated.
MATERIALS AND METHODS

Compounds, culture medium, and irradiation
Sanazole was provided by Prof. V. T. Kagiya, Kyoto University. Nimorazole (4-(2-(5-nitro-1 H -1-imidazolyl)ethyl)morpholine) was newly synthesized by us (YU, HN, HH). Briefly, it was prepared in three steps from 4(5)-nitroimidazole as a starting material as follows. Hydroxyethylation of 4(5)-nitroimidazole with ethylene oxide under acidic conditions afforded the 2-(5-nitro-1 H -1-imidazolyl)-1-ethanol, followed by an phosphorous tribromide-catalyzed bromination of the resultant primary alcohol to obtain the 1-(2-bromoethyl)-5-nitro-1 H -imidazole. Finally, treatment of the bromide with morpholine in toluene afforded nimorazole as a light yellow needle (mp 110-110.5 ∞ C) in overall yield of 37%. KU-2285 was supplied by Daikin Co. Ltd. (Osaka, Japan). Figure 1 shows chemical structures of the three sensitizers, and Table 1 summarizes characteristics of the three sensitizers. Eagle's minimum essential medium (MEM, Nissui Seiyaku Co., Tokyo, Japan) supplemented with 12.5% fetal bovine serum (JRH Biosciences, Inc., Kansas, USA) was used throughout the experiments. Irradiation was performed using a 210-kVp X-ray machine (10 mA with a 2-mm Al filter; Chubu Medical Co., Matsusaka, Japan) at a dose rate of 2 Gy/min.
In vitro study
In experiments under aerobic conditions, exponentially growing SCCVII tumor cells (a squamous cell carcinoma line in C3H mice) were harvested from the standard cell culture dishes by trypsinization, and appropriate numbers of SCCVII cells (e.g., 10,000 cells at 8.5 Gy) were plated in 50 mm dishes 6 h before irradiation. At 30 min before irradiation, phosphate-buffered saline (PBS) or the sensitizers dissolved in PBS were added to the dishes at 1 mM, and irradiated. After irradiation, the dishes were washed with PBS and medium was replaced with a new one.
In experiments under hypoxic conditions, exponentially growing SCCVII tumor cells were harvested from the standard cell culture dishes by trypsinization, and the cells were suspended in glass test tubes containing 0.25 ml of MEM (2 ¥ 10 5 cells/ml) with the sensitizers (0.5 and 1 mM). Then, they were made hypoxic by flushing 95% N 2 /5% CO 2 gas for 40 min before irradiation at room temperature, as described previously. 32) After irradiation at 10-25 Gy, the sensitizer was removed and the cells were plated (e.g., 10,000 cells at 17 Gy with the sensitizers and at 25 Gy without the sensitizers). In both experiments under aerobic and hypoxic conditions, cell surviving fractions were determined by the standard in vitro colony formation assay. The sensitizer enhancement ratio (SER) was calculated from two radiation doses with or without sensitizer to reduce cell survival to 1%.
In vivo study
Exponentially growing SCCVII tumor cells cultured in vitro were transplanted subcutaneously in the right hind legs (2 ¥ 10 5 cells per leg) of 8-week-old female C3H/HeN mice. When the tumor reached 1 cm in diameter, experiments were performed. All sensitizers were administered intraperitoneally 30 min before irradiation. This timing was chosen according to the results of previous studies. 16, 17, 24, 25) With prior administration of 100, 200 or 400 mg/kg of the drugs (dissolved in PBS at 5, 10, and 20 mg/ml, respectively), the tumor-bearing leg of the mice was fixed with adhesive tape without anesthesia, and irradiated at 20 Gy. As controls, the mice were also irradiated at 20 or 30 Gy with prior administration of PBS. The three dimensions of each tumor were measured every other day with calipers, and the tumor volume was estimated using the formula p /6 x product of the three dimensions. The tumor growth time (TGT) was defined as the time required after the first day of treatment for a tumor to reach twice the initial volume, and the tumor growth delay time (TGDT) was defined as the TGT in each treated mouse minus the mean TGT in the control group. Twelve mice were used for each treated group, while six mice were used for unirradiated control groups.
Statistical analysis
Differences between pairs of cell survival curves and growth delay curves were examined by analysis of covariance, which was carried out using a computer program Stat View Version 5.0 (SAS Institute Inc., Cary, NC, USA). Table 2 show results of in vitro studies and radiobiological parameters, respectively. All compounds had no cytotoxic effects under both aerobic and hypoxic conditions at the concentrations used in this study (data not shown). All three compounds had no sensitizing effect under aerobic conditions at 1 mM, but all had significant effect under hypoxic conditions. The SER at 1 mM for sanazole, nimorazole and KU-2285 was 1.55, 1.45 and 1.95, respectively. KU-2285 was more efficient than sanazole and nimorazole (p = 0.016 and 0.0089, respectively), but there was no significant difference between sanazole and nimorazole. At 0.5 mM, the SER for sanazole, nimorazole and KU-2285 was 1.4, 1.4 and 1.75, respectively. Also at this concentration, KU-2285 was more efficient than sanazole and nimorazole (p = 0.023 and 0.0053, respectively). Figures 3 show results of growth delay experiments to test the effect of the three sensitizers at doses of 100, 200, and 400 mg/kg. Table 3 shows TGDT after each treatment. At the dose of 100 mg/kg, KU-2285 was more efficient than nimorazole (p = 0.0016). At 200 mg/kg, KU-2285 was more efficient than sanazole (p = 0.013) and nimorazole (p < 0.0001), and sanazole was more efficient than nimorazole (p = 0.0022). At 400 mg/kg, KU-2285 and sanazole were more efficient than nimorazole (p = 0.0005 and 0.023, respectively). There were no significant differences between other pairs of the three sensitizers.
RESULTS
Figure 2 and
DISCUSSION
Although sanazole and nimorazole have been used for clinical studies, experimental data on these two compounds, especially on their in vivo efficacy, have been rather scarce. In 1986, Shibamoto et al. 25) reported screening results of various 3-nitrotriazole compounds, in which sanazole had apparent radiosensitizing effects both in vitro and in vivo , but its effects were inferior to those of misonidazole. After this study, basic studies on this compound have been performed, [26] [27] [28] [29] and a few studies regarding in vivo efficacy were also published. 26, 29) However, most studies did not compare in vivo efficacy of sanazole with that of other wellknown compounds such as misonidazole and etanidazole. Thus, previous data appeared to be insufficient for us to choose this compound for clinical study. In the 1980's, Overgaard et al. 24) investigated nimorazole in comparison with misonidazole, and found that nimorazole was almost as efficient as misonidazole at a low drug dose of 100 mg/kg in murine tumors. At higher doses, however, nimorazole appeared to become less efficient than misonidazole. Since relatively high single sensitizer doses will be administered when they are combined with stereotactic radiosurgery, these data on nimorazole appeared also insufficient to start such clinical studies. Thus, we carried out this investigation on the efficacy of these two compounds.
The three compounds investigated in the present study have different nitroheterocyclic rings, but their mechanism of action (i.e., electron-affinic sensitization) is considered to be similar. KU-2285 has two fluorines on its side chain, and they may contribute to produce higher cytotoxicity and sensitizing activity. In the present study, all the three compounds had definite sensitizing effects. In vivo , all three sensitizers showed relatively small dose-dependency, so that clinical efficacy of these sensitizers may be expected even at low drug doses when combined with a large single radiation dose such as 20 Gy used in this study. Sanazole appeared to be slightly more efficient than nimorazole and slightly less efficient than KU-2285. Its lower efficacy as compared with that of KU-2285 was well anticipated from the results of previous studies, 16, 17, 19, 25) but the difference in effect between the two compounds was not so great as we expected. 5-nitroimidazoles such as metronidazole are known to be less efficient than 2-nitroimidazoles, 33) and indeed, a 5-nitroimidiazole nimorazole was less efficient than a 2-nitroimidazole derivative KU-2285 at the concentrations and doses used in this study. The effects of 3-nitrotriazoles have not been well clarified, because they have been less often investigated than 2-nitroimidazoles. [25] [26] [27] [28] [29] The present study would suggest that 3-nitrotriazoles may not be much inferior to 2-nitroimidazoles in terms of efficacy. Although it seems difficult to obtain KU-2285 for clinical studies because of its high cost, sanazole can be provided much more cheaply and readily than KU-2285 (Table 1) . Sanazole is known to be not so toxic in mice, with a 50% lethal dose of 1.9 g/kg in Balb/c mice (Table 1) . 25) Considering the relatively high in vivo effects and the low toxicity in mice of sanazole, it seems reasonable to plan clinical studies with sanazole. Since encouraging results have been reported for KU-2285 when used at the time of intraoperative radiotherapy, 13) sanazole may prove effective for human tumors when combined with a single high-dose irradiation. Stereotactic radiosurgery is widely spreading, and now it plays an important role in the treatment of not only brain neoplasms but also early lung cancer. 34) Tumors larger than 3 cm are often treated with radiosurgery, and in such cases, combination with a hypoxic cell radiosensitizer is expected to improve local control. We are now preparing to start clinical studies of the combination of sanazole and radiosurgery, especially for T2 cases (tumor diameter > 3 cm) of stage I non-small cell lung cancer, considering the increasing importance of this new treatment modality as an alternative to surgery. In humans, it has been shown that sanazole can be safely administered up to a dose of 10 g/m 30, 31) but the maximum tolerated single dose, when combined with radiosurgery, is unknown. We will first determine it and then evaluate the efficacy of sanazole.
